Onkologie. 2017:11(5):232-235 | DOI: 10.36290/xon.2017.044

Serous tubal intraepithelial carcinoma (STIC)

Gabriel Jelenek, Josef Chovanec
Klinika operační onkologie, Oddělení gynekologické onkologie Masarykova onkologického ústavu a LF MU v Brně

High-grade serous carcinomas (HGSC) are group of ovarial, tubal and peritoneal tumors arising from precursor lession most likelyfrom distal part of the fallopian tube. At the time of diagnosis of HGSC are women affected with metastatic sprej of the tumorinto abdominal cavity with 5 year survival of 10–30%. Among women with increased risk of HGSC (the most with BRCA mutation)witch underwent bilateral salpingo-oophorectomy is 4–17% diagnosed with STIC (serous tubal intraepithelial carcinoma) or withinvasive neoplasia a aproximately 80% those tumors are found in ampular part of the fallopian tube.

Keywords: high grade serous carcinoma (HGSC), serous tubal intraepithelial carcinoma (STIC), BRCA, STIL, TILT, SCOUT, SEE-FIM

Published: November 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Jelenek G, Chovanec J. Serous tubal intraepithelial carcinoma (STIC). Onkologie. 2017;11(5):232-235. doi: 10.36290/xon.2017.044.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. van der Kolk DM, et al. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age. Breast Cancer Res Treat. 2010; 124(3): 643. Go to original source... Go to PubMed...
    2. Morrison JC, Blanco LZ, Vang R, et al. Incidental serous tubal intraepithelial carcinoma and early invasive serous carcinoma in the analysis of a case series, Am J surg pathol 2015; 39: 442-453. Go to original source... Go to PubMed...
    3. Kim A, et al. Review: Therapeutic strategies in epithelial ovarian cancer. Exp Clin Cancer Res. 2012 13; 31(1): 14. Go to original source... Go to PubMed...
    4. Stirling D, et al. Screening for familial ovarian cancer: failure of current protocols to detect ovarian cancer at an early stage according to the international Federation of gynecology and obstetrics system. J Clin Oncol 2005; 23(24): 5588-96. Go to original source... Go to PubMed...
    5. American Cancer Society. Cancer Facts and Figures 2013. Atlanta, Ga: American Cancer Society. Available online. Last accessed May 2, 2013.
    6. Zhang S, et al. Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol Oncol. 2011; 121(2): 353. Go to original source... Go to PubMed...
    7. Evans DG, et al. Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers. J Med Genet. 2009; 46(9): 593. Go to original source... Go to PubMed...
    8. Kauff ND, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2002; 346(21): 1609. Go to original source...
    9. Bijron JG, et al. Fallopian Tube Intraluminal Tumor Spread From Noninvasive Precursor Lesions: A Novel Metastatic Route in Early Pelvic Carcinogenesis. Am J Surg Pathol. 2013 May 2. [Epub ahead of print] Go to original source... Go to PubMed...
    10. Li HX, Lu ZH, Shen K, et al. Advances in serous tubal intraepithelial carcinoma: correlation with high grade serous carcinoma and ovarian carcinogenesis, Int. J. Clin. Exp. Pathol. 2014; 74: 848-857.
    11. Medeiros F, Mutto MG, Lee Y, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome, Am J. Surg. Pathol. 2006; 30: 230-236. Go to original source... Go to PubMed...
    12. Cass I, Holschneider C, Datta N, et al. BRCA-mutation-asssociated fallopian tube carcinoma: a distinct clinical phenotype? Obstet Gynecol 2005; 106: 1327-1334. Go to original source... Go to PubMed...
    13. Gilks CB, Irving J, Kobel M, et al. Incidental nonuterine high-grade serous carcinomas arise in the fallopian tube in most cases: further evidence for the tubal origin of high-grade serous carcinomas: Am J Surg Pathol 2015; 39: 357-364. Go to original source... Go to PubMed...
    14. Przybycin CG, Kurman RJ, Ronnett BM, et al. Are all pelvic (nonuterine) serous carcinomas of the tubal origin? Am J Surg pathol 2010; 34: 1407-1416. Go to original source... Go to PubMed...
    15. Gilbert L, Basso O, Sampalis J, et al. Assesment of symptomatic women for early diagnosis of ovarian cancer: results from the prospective DOvE pilot project. Lancet Oncol 2012; 13: 285-291. Go to original source...
    16. Vang R, Shih IeM, Kurman RJ. Fallopian tube precursors of ovarian low- and high-grade serous neoplasms. Histopathology 2013; 62: 44-58. Go to original source... Go to PubMed...
    17. Wethington SL, Park KJ, Soslow RA, et al. Clinical outcome of isolated serous tubal intraepithelial carcinomas (STIC), Int J. Gynecol. Cancer. 2013; 23: 1603-1611. Go to original source... Go to PubMed...
    18. Chen LM, STIC-ing with what we know, Gynecologic Oncology. 2016; 143(2): 227-228. Go to original source...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.